乳腺癌中的TP53凋亡生物标志物
本文综述了将TP53凋亡检测应用于标准临床标本的实验室方法,涵盖FFPE、新鲜冰冻样本及液体活检系统,涉及靶向NGS、ddPCR、多重RT及IHC等技术,检测限低于0.5% VAF,转移病例中组织与ctDNA一致率为87%。
要点
- 靶向NGS、ddPCR和多重RT检测限低于0.5% VAF,需正交方法确认。
- IHC检测p53、BAX和cleaved caspase-3可定量评估凋亡。
- 转移病例中组织与ctDNA在不同平台间一致率为87%。
核心结论
- 将TP53凋亡数据从研究工具转化为经确认的检测,可用于乳腺癌治疗和未来研究。
研究设计与样本
- 综述,汇编将TP53凋亡检测应用于标准临床标本的实验室方法。
主要发现
- 靶向NGS、ddPCR和多重RT检测限低于0.5% VAF,并有正交确认方法支持。
- IHC检测p53、BAX和cleaved caspase-3可提供标准病理样本中凋亡的可量化指标。
- 转移病例中组织与ctDNA在不同平台间一致率为87%。
关键数值与推荐
- 检测限低于0.5% VAF。
- 转移病例中组织与ctDNA一致率为87%。
临床怎么用
- 整合基因组变异与通路水平特征以提升预后、治疗决策和MRD监测的临床解读。
- 实施标准化分析前控制、方法验证及一致报告系统以达到实验室认证要求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumor protein p53 (TP53) plays a crucial role in regulating apoptosis and maintaining genomic stability, making TP53-mediated cell death an important diagnostic marker for breast cancer therapy. This review compiles laboratory methodologies for the application of TP53 apoptosis assays to standard clinical specimens. Modern diagnostic techniques enhance the management of formalin-fixed paraffin-embedded (FFPE) and fresh-frozen (FF) samples, as well as liquid biopsy systems, to preserve nucleic acid integrity for subsequent analysis. Analytical platforms, including targeted next-generation sequencing (NGS), droplet digital polymerase chain reaction (ddPCR), and multiplex reverse transcription (RT), exhibit high sensitivity, achieving detection limits below 0.5 % variant allele fraction (VAF), and are supported by orthogonal confirmation methods. Immunohistochemical (IHC) assays employing proteins such as p53, BCL2-associated X protein (BAX), and cleaved caspase-3 provide quantifiable indicators of apoptosis in standard pathological sample. Integrating genomic variants with pathway-level signatures enhances the clinical interpretation of prognosis, therapeutic decision-making, and monitoring of minimal residual disease (MRD). Achieving laboratory accreditation necessitates the implementation of standardized preanalytical controls, validation of methods with clearly defined analytical performance criteria, and establishment of consistent reporting systems. In metastatic disease cases, there is an 87 % concordance between tissue and circulating tumor DNA (ctDNA) across various platforms, supporting its clinical application. This approach translates TP53-apoptosis data from research tools into validated tests for clinical application in breast cancer treatment and future research initiatives.
引用
- Rafeeq M, Afzal M, Al-Abbasi FA, et al. TP53 apoptosis biomarkers in breast cancer. Clin Chim Acta. 2025. PMID: 41135852. doi:10.1016/j.cca.2025.120678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。